[

icmr-bharat biotech

]
The vaccine manufacturer declared on Wednesday that as per preliminary results of the phase 3 clinical trial Covaxin possess an efficacy of 81% .(Amal KS/ Hindustan Times)

Covaxin demonstrates prowess of Atmanirbhar Bharat, says ICMR chief

By hindustantimes.com | Edited by Ayshee Bhaduri, Hindustan Times, New Delhi
PUBLISHED ON MAR 03, 2021 08:01 PM IST
  • Bharat Biotech developed the country’s first indigenous vaccine, Covaxin, in partnership with ICMR.
The SARS-CoV-2 strain that causes Covid-19 was isolated in the ICMR-National Institute of Virology (NIV), Pune, and transferred to Bharat Biotech in May.(REUTERS)
The SARS-CoV-2 strain that causes Covid-19 was isolated in the ICMR-National Institute of Virology (NIV), Pune, and transferred to Bharat Biotech in May.(REUTERS)

ICMR-Bharat Biotech to expedite clinical trials of Covid-19 vaccine, plan launch by August 15

Hindustan Times, New Delhi | By Rhythma Kaul
UPDATED ON JUL 03, 2020 11:26 AM IST
ICMR is working in collaboration with pandemic vaccine leader, Bharat Biotech, to develop this vaccine against Covid-19.
SHARE
Story Saved